Okasa Pharma Profile
Key Indicators
- Authorised Capital ₹ 10.50 Cr
as on 11-12-2024
- Paid Up Capital ₹ 2.20 M
as on 11-12-2024
- Company Age 34 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.25 Cr
as on 11-12-2024
- Revenue -83.99%
(FY 2023)
- Profit 93.57%
(FY 2023)
- Ebitda -5.20%
(FY 2023)
- Net Worth -0.20%
(FY 2023)
- Total Assets -0.20%
(FY 2023)
About Okasa Pharma
The Company is engaged in the Metals And Minerals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.50 Cr and a paid-up capital of Rs 2.20 M.
The company has closed loans amounting to ₹5.25 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Raman Athipotta and Srinivas Hariharan serve as directors at the Company.
- CIN/LLPIN
U24239MH1990PTC071153
- Company No.
071153
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
25 May 1990
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Okasa Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raman Athipotta  | Director | 31-Jan-2015 | Current |
| Srinivas Hariharan | Director | 04-Sep-2002 | Current |
Financial Performance of Okasa Pharma.
Okasa Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 83.99% decrease. The company also saw a substantial improvement in profitability, with a 93.57% increase in profit. The company's net worth dipped by a decrease of 0.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Okasa Pharma?
In 2023, Okasa Pharma had a public holding of 13.10%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 16 Nov 2004 | ₹3.75 Cr | Satisfied |
The Saraswat Co Operative Bank Ltd Creation Date: 04 Jan 1993 | ₹1.50 Cr | Satisfied |
How Many Employees Work at Okasa Pharma?
Okasa Pharma has a workforce of 1 employees as of Apr 03, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Okasa Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Okasa Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
.webp){kind=small}
